Login to Your Account



Enanta's $20M: VC Funding, Equity Stake From Shionogi

By Kim Coghill


Wednesday, September 1, 2004
Enanta Pharmaceuticals Inc. raised $20 million in new financing to help carry its lead candidate, EP-013420, a first-in-class bridged bicyclic ketolide antibiotic for community respiratory tract infections, through Phase I development. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription